10-Q: ALT5 Sigma Reports Q3 Surge Driven by Crypto Assets, Acquisitions

ALT5 Sigma Corporation announced significant revenue growth and net income for Q3 2025, primarily fueled by its new WLFI cryptocurrency treasury program and recent Fintech acquisitions, despite increased operating expenses and ongoing legal challenges.

Summary

• ALT5 Sigma Corporation (formerly JanOne Inc., ticker ALTS) reported a net income of $48.96 million for the 13 weeks ended September 27, 2025, a substantial improvement from a net loss of $0.82 million in the prior year period.
• Revenue for the 13 weeks ended September 27, 2025, increased by approximately $2.6 million to $7.58 million, driven by increased business activity at ALT5 Subsidiary and the acquisition of Mswipe.
• The company recognized a significant unrealized gain of approximately $72.8 million on its WLFI cryptocurrency assets for the 13 and 39 weeks ended September 27, 2025, following the initiation of its WLFI Treasury Program.
• Total assets surged to $1.64 billion as of September 27, 2025, from $82.44 million at December 28, 2024, primarily due to the acquisition of cryptocurrency assets.
• The Biotechnology segment (Alyea Therapeutics Corporation) has been presented as discontinued operations, with the company intending to capitalize and spin off this subsidiary.
• ALT5 Sigma completed a $1.5 billion financing in August 2025, consisting of a registered direct offering ($750 million cash) and a concurrent private placement (receipt of $750 million in WLFI tokens).
• The company's disclosure controls and procedures were deemed not effective as of September 27, 2025, due to material weaknesses in written documentation and insufficient resources for segregation of duties.
• A judgment of $1.3 million plus interest was entered against ALT5 Sigma on October 3, 2025, in the Main/270 litigation, which the company is appealing.
• A settlement was reached in the Gulf Coast Bank and Trust litigation for $975,000, funded by a $900,000 cash bond and a $75,000 cash payment made on December 1, 2025.
• The company received a Nasdaq delinquency notification on January 7, 2026, for failing to hold its annual meeting within 12 months, with the meeting now scheduled for February 27, 2026.

Sentiment

Score: 6

Explanation: The significant net income driven by cryptocurrency asset gains and successful capital raise are strong positives. However, the underlying operational losses (Adjusted EBITDA), substantial increase in SG&A, ongoing legal challenges, and material weaknesses in internal controls temper the overall positive sentiment. The going concern warning also adds a layer of caution.

Positives

• Net income significantly improved to $48.96 million for the 13 weeks ended September 27, 2025, compared to a net loss of $0.82 million in the prior year.
• Revenue increased by approximately $2.6 million for the 13 weeks ended September 27, 2025, and by $12.4 million for the 39 weeks ended September 27, 2025, driven by Fintech acquisitions.
• The WLFI Treasury Program generated a substantial unrealized gain of $72.8 million on cryptocurrency assets for both the 13 and 39 weeks ended September 27, 2025.
• Strategic acquisitions of ALT5 Subsidiary and Mswipe have expanded the company's Fintech capabilities and market reach.
• The company successfully completed a $1.5 billion capital raise, significantly bolstering its financial position and funding the WLFI Treasury Strategy.
• The accumulated deficit improved from $(56.88) million at December 28, 2024, to $(19.89) million at September 27, 2025.
• Settlement reached in the Gulf Coast Bank and Trust litigation for $975,000, resolving a significant legal contingency.

Negatives

• Selling, general and administrative expenses increased substantially by $16.07 million for the 13 weeks and $20.48 million for the 39 weeks ended September 27, 2025, primarily due to bad debt, stock-based compensation, and acquisition costs.
• Operating loss worsened to $(16.54) million for the 13 weeks and $(20.26) million for the 39 weeks ended September 27, 2025, compared to prior year periods.
• Adjusted EBITDA decreased significantly to $(9.13) million for the 13 weeks and $(10.85) million for the 39 weeks ended September 27, 2025, indicating a decline in operational profitability excluding non-cash items.
• Interest expense, net, increased by approximately $1.1 million for the 13 weeks and $2.1 million for the 39 weeks ended September 27, 2025, reflecting higher debt-related costs.
• The Biotechnology segment, now discontinued operations, reported increased net losses of $(1.84) million for the 39 weeks ended September 27, 2025.
• The company's disclosure controls and procedures were found to be ineffective due to material weaknesses, raising concerns about financial reporting reliability.
• A final judgment of $1.3 million plus interest was entered against the company in the Main/270 litigation, requiring an appeal.
• ALT 5 Sigma Canada Inc. was found guilty of money laundering in Rwanda, resulting in the forfeiture of US$3.5 million and an order for dissolution, which is under appeal.
• Significant dilution occurred with common stock outstanding increasing from 15.42 million to 126.09 million shares.
• The company received a Nasdaq delinquency notice for failing to hold its annual meeting, indicating a corporate governance issue.

Risks

• The company's ability to continue as a going concern is dependent on securing future capital raises or structured arrangements for its biotechnology segment and day-to-day operations.
• Material weaknesses in internal control over financial reporting, including insufficient written documentation and resources for segregation of duties, pose risks to the reliability of financial reporting.
• Ongoing legal proceedings, such as the Sieggreen class action and First Capital Consulting litigation, could result in significant liabilities and legal expenses.
• The appeal of the $1.3 million judgment in the Main/270 litigation carries uncertainty regarding the final outcome and potential financial impact.
• The forfeiture of US$3.5 million and the dissolution order for ALT 5 Sigma Canada Inc. in Rwanda, despite being appealed, represent a substantial financial loss and operational risk.
• The WLFI Treasury Program's value is subject to the volatility of cryptocurrency markets and the adoption of the USD1 stablecoin, which could impact the company's financial performance.
• Future capital raises may further dilute the ownership interest of existing stockholders.
• The company's reliance on third-party liquidity providers for its Fintech segment exposes it to counterparty risk and potential disruptions in service.

Future Outlook

The company intends to capitalize a subsidiary (Alyea Therapeutics Corporation) with certain biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary to operate on a stand-alone basis. The WLFI Treasury Strategy involves a committed long-term 'HODL' approach, with future acquisitions funded through operating cash flows, structured debt, and selective capital raises, and sales restricted to liquidity requirements or material portfolio rebalancing events. The company may require additional debt financing and/or capital for new acquisitions, Phase IIb clinical trials for JAN123, or other strategic investments.

Management Comments

• "Our policy remains a committed long-term HODL approach, with future acquisitions funded through operating cash flows, structured debt, and selective capital raises. Sales are restricted to liquidity requirements or material portfolio rebalancing events."
• "Our ability to continue as a going concern is dependent upon the success of future capital raises or structured settlements and cash flows from the acquisition of ALT5 Subsidiary to fund the required testing to obtain FDA approval of JAN 123, as well as to fund our day-to-day operations."
• "We strongly dispute and deny the allegations contained in the Second Amended Complaint [Sieggreen litigation] and will continue to defend itself vigorously against the claims."
• "The Company disputes the allegations concerning the Company [Virland Johnson bankruptcy] and will vigorously defend itself against the claims."
• "Although no assurance can be given as to the outcome of the appeal [Rwanda litigation], the Company and ALT 5 Sigma Canada Inc. are actively pursuing all available legal remedies to protect their interests and those of their stakeholders."

Industry Context

ALT5 Sigma is strategically positioning itself at the intersection of traditional finance and the burgeoning crypto economy through its Fintech segment, which includes crypto payment gateways and multi-currency card services. The substantial investment in WLFI tokens reflects a broader trend of institutional adoption and treasury management strategies involving digital assets, aiming to leverage the growth of decentralized finance (DeFi) and stablecoins like USD1. The spin-off of its Biotechnology segment (Alyea) allows for a focused approach on non-addictive pain treatments, aligning with the specialized nature of the biotech industry and the pursuit of orphan drug designations for niche markets. This diversification, while offering potential growth, also introduces complexity and exposure to distinct market risks.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable company data to assess results against global standards.
• The significant unrealized gain on cryptocurrency assets is a unique factor tied to the company's specific WLFI treasury strategy, making direct comparison to traditional financial services or biotech companies challenging without more context on crypto market performance relative to peers.
• The ineffectiveness of disclosure controls and procedures and the Nasdaq delinquency notice for not holding an annual meeting are below industry best practices for corporate governance and financial reporting standards for publicly traded companies.

Management Changes

Corporate Governance

Legal Proceedings

• SEC Complaint: Settled on May 28, 2024. The company agreed to a permanent injunction against violating Section 10(b) of the Exchange Act and Rule 10b-5, and to pay a civil penalty of $250,000 in four quarterly payments of $62,500. A balance of $250,000 remained as of September 27, 2025. Remaining allegations are against the former CFO, Virland Johnson.
• Sieggreen Litigation: A class action lawsuit where the company was added as a defendant on March 6, 2023. Plaintiff alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5. The company's Motion to Dismiss the Second Amended Complaint was denied on September 30, 2025, and the company filed its Answer on December 1, 2025. The company disputes the allegations.
• Main/270 Litigation: A lawsuit where the company is a defendant as a guarantor for a lease. A final judgment was entered against ALT5 Sigma on October 3, 2025, for $1.3 million plus pre and post-judgment interest. The company filed an appeal with the United States Court of Appeals for the Sixth Circuit on November 3, 2025.
• Gulf Coast Bank and Trust vs. ALT5 Sigma Corporation, et al.: Plaintiff sought approximately $1.6 million related to a loan guarantee. Subsequent to September 27, 2025, the parties reached a settlement agreement for $975,000, funded by a $900,000 cash bond and a $75,000 cash payment completed on December 1, 2025.
• Virland Johnson Bankruptcy: An Adversary Proceeding filed on August 6, 2025, received on August 14, 2025, seeking to recover 329,294 shares of common stock awarded to the company's former CFO, Virland Johnson, which were not disclosed in his bankruptcy petition. The company filed its Answer on September 30, 2025, denying wrongdoing.
• First Capital Consulting, Inc. DBA Trusaic vs. ALT5 Sigma Corporation: Trial is scheduled for June 29, 2026. Plaintiff is seeking $97,696 for unpaid obligations of former subsidiaries. The company believes it is not responsible for these fees.
• Rwanda Litigation: ALT 5 Sigma Canada Inc., an indirect subsidiary, was found guilty of inability to justify the origin of assets and money laundering on May 7, 2025, by the Intermediate Court of Nyarugenge, Rwanda. The court ordered the permanent forfeiture of US$3.5 million to the Rwandan State Treasury and the dissolution of ALT 5 Sigma Canada Inc. The company and a co-defendant appealed this decision to the High Court of Kigali, Rwanda, on June 6, 2025. The company has recorded a US$3.5 million allowance on its balance sheets.

Related Party Transactions

• Shared Services: The company shares certain executive, accounting, and legal services with Live Ventures Incorporated. Tony Isaac (Company's President) is the father of Jon Isaac (President and CEO of Live Ventures and managing member of Isaac Capital Group LLC (ICG)), and Tony Isaac is also a director of Live Ventures. Total shared services were approximately $117,000 for the 39 weeks ended September 27, 2025.
• Office Lease: ALT5 rents approximately 9,900 square feet of office space from Live Ventures in Las Vegas, Nevada.
• Promissory Notes with Live Ventures and ICG: On February 7, 2024, the company entered into promissory notes with Live Ventures and ICG, each for an initial principal of $300,000 at 10% interest, convertible at $0.61 per share. As of September 27, 2025, the Live Note balance was $0, and the ICG Note balance was approximately $30,000, with portions converted into common stock.
• Short-Term Advances from ICG: On April 18, 2024, ICG made a $0.1 million short-term demand advance at 10% interest. The outstanding principal was $23,000 as of September 27, 2025.
• Short-Term Advances from Novalk Apps SAA, LLP: On May 28, 2024, and June 3, 2024, Novalk Apps SAA, LLP (managed by Juan Yunis, an employee of Live Ventures) made short-term demand advances of $120,000 and $100,000, respectively, at 10% interest. The outstanding principal was approximately $0.1 million as of September 27, 2025.

Stakeholder Impact

• Shareholders: Experienced significant dilution due to the issuance of over 100 million new common shares in the recent capital raise. The substantial unrealized gain on crypto assets positively impacted net income and equity, but operational losses and legal risks remain. The Nasdaq delinquency notice could impact investor confidence.
• Employees: The company's focus on Fintech acquisitions and the spin-off of the Biotech segment may lead to shifts in employment focus and structure. Stock-based compensation is a notable expense.
• Customers: The acquisition of Mswipe expands multi-currency and crypto-enabled payment card services, potentially offering enhanced solutions. The WLFI Treasury Program aims to accelerate real-world utility for WLFI, potentially benefiting users of the ecosystem.
• Creditors: The company's liquidity is dependent on future capital raises, and there are ongoing negotiations for revised maturity dates on certain debentures. The settlement of the Gulf Coast Bank and Trust litigation resolves one creditor claim.
• Regulatory Authorities: The SEC settlement and ongoing Nasdaq compliance issues highlight regulatory scrutiny and the need for robust internal controls and timely reporting.

Next Steps

• File a plan with Nasdaq regarding regaining compliance for the annual meeting deficiency within 45 days of January 7, 2026.
• Hold the Annual Meeting of Stockholders on February 27, 2026, to cure the Nasdaq deficiency.
• Continue to pursue all available legal remedies in the Rwanda litigation appeal.
• Vigorously defend against claims in the Sieggreen class action and Virland Johnson bankruptcy adversary proceeding.
• Continue to appeal the $1.3 million judgment in the Main/270 litigation.
• Prepare for the trial in the First Capital Consulting, Inc. DBA Trusaic litigation scheduled for June 29, 2026.
• Remedy the identified material weaknesses in internal control over financial reporting.
• File a registration statement for the resale of the PIPE Securities within 15 days of the Private Placement closing (overdue as of filing date).
• Evaluate and potentially pursue additional debt financing and/or capital to fund new acquisitions, Phase IIb clinical trials for JAN123, or other strategic investments.
• Proceed with the intention to capitalize and spin off the Biotechnology segment (Alyea Therapeutics Corporation).

Key Dates

Recommendation

ALT5 Sigma presents a mixed financial picture. The substantial net income and asset growth driven by the WLFI crypto treasury program and successful capital raise are significant positives, indicating strong strategic execution in the digital asset space. However, these gains are largely unrealized and subject to crypto market volatility. The underlying operational performance, as reflected by the negative Adjusted EBITDA and soaring SG&A expenses, remains a concern. Furthermore, the company faces significant corporate governance issues, including ineffective internal controls and a Nasdaq delinquency notice, alongside multiple ongoing and recently settled legal proceedings that could incur further costs or liabilities. The 'going concern' warning underscores the reliance on future capital raises. While the crypto strategy offers high upside potential, the operational and governance risks suggest a 'hold' recommendation, advising investors to monitor the resolution of internal control issues, legal outcomes, and the sustained profitability of the Fintech segment beyond unrealized crypto gains before making further investment decisions.

Keywords

Fintech, Cryptocurrency, Blockchain, WLFI, Mswipe, SEC Filing, 10-Q, Financial Results, Capital Raise, Biotechnology, Alyea Therapeutics, Corporate Governance, Legal Proceedings, Internal Controls, Digital Assets, Payment Solutions